Morcellation in gynecologic oncology

Area of Science:

• Gynecologic oncology
• Surgical safety
• Medical device regulation

Background:

• Morcellation of uteri with unsuspected malignancies has been a long-standing concern.
• Recent FDA statements have prompted more intensive evaluation of clinical outcomes and practice changes regarding power morcellators.
• This review synthesizes key publications on the topic.

Purpose of the Study:

• To summarize relevant publications on the clinical outcomes and practice impacts related to uterine morcellation, particularly concerning unsuspected malignancies.
• To review the current recommendations and evidence regarding the use of power morcellators in gynecologic surgery.

Main Methods:

• Literature review of relevant publications.
• Synthesis of findings from professional society guidelines (Society of Gynecologic Oncology, American College of Obstetricians and Gynecologists).
• Analysis of reported clinical outcomes, complication rates, and societal costs associated with uterine morcellation.

Main Results:

• Professional societies recommend against morcellation when malignancy is suspected or diagnosed, acknowledging limitations in detecting occult leiomyosarcoma.
• Accurate incidence of occult leiomyosarcoma remains unknown due to poor data quality.
• FDA safety communications have led to decreased laparoscopic hysterectomy rates, with reported increases in complication rates and societal costs for abdominal procedures.

Conclusions:

• Clinical judgment and adherence to guidelines based on scientific evidence are recommended.
• Patients must be informed about the limitations of current data regarding occult malignancies and diagnostic testing.
• Minimally invasive surgery, avoiding morcellation when malignancy is suspected, is associated with better outcomes and quality of life; research should focus on improving diagnostic accuracy and therapeutic efficacy.